Profile data is unavailable for this security.
About the company
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD-9.38m
- Incorporated2011
- Employees8.00
- LocationPhio Pharmaceuticals Corp11 APEX DRIVE, SUITE 300A, PMB 2006MARLBOROUGH 01752United StatesUSA
- Phone+1 (508) 767-3861
- Fax+1 (508) 767-3862
- Websitehttps://phiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tharimmune Inc | 0.00 | -8.89m | 3.73m | 2.00 | -- | 0.5291 | -- | -- | -111.65 | -111.65 | 0.00 | 8.97 | 0.00 | -- | -- | 0.00 | -130.60 | -- | -173.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.98 | -- | -- | -- |
| Exicure Inc | 21.77m | 2.97m | 3.84m | 6.00 | 0.2597 | 0.8543 | 0.9912 | 0.1765 | 1.71 | 1.71 | 3.07 | 0.52 | 1.04 | -- | -- | 1,674,923.00 | 14.17 | -41.75 | 42.53 | -55.57 | -- | -- | 13.64 | -302.07 | -- | -- | 0.00 | -- | 6,068.12 | 24.29 | 95.97 | -- | -59.57 | -- |
| Sentient Brands Holdings Inc | 0.00 | -818.63k | 3.86m | 2.00 | -- | -- | -- | -- | -0.0145 | -0.0145 | 0.00 | -0.036 | 0.00 | 0.0188 | -- | 0.00 | -317.87 | -220.36 | -- | -- | -- | 41.81 | -- | -31,451.19 | 0.0354 | -2.27 | -- | -- | -73.68 | -- | 34.98 | -- | -- | -- |
| Cyclacel Pharmaceuticals Inc | 449.00k | -19.85m | 3.86m | 12.00 | -- | -- | -- | 8.60 | -21.99 | -21.99 | 0.4636 | -1.67 | 0.0318 | -- | 0.1204 | -- | -139.57 | -57.58 | -314.22 | -69.81 | -- | -- | -4,386.86 | -18,789.29 | -- | -128.51 | -- | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 3.96m | 24.00 | -- | -- | -- | 0.2784 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -9.38m | 3.98m | 8.00 | -- | 0.5981 | -- | -- | -3.71 | -3.71 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -113.26 | -71.92 | -145.23 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Alzamend Neuro Inc | 0.00 | -12.40m | 4.06m | 4.00 | -- | -- | -- | -- | -1.87 | -1.87 | 0.00 | -0.572 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| Evoke Pharma Inc | 6.11m | -7.13m | 4.08m | 4.00 | -- | 1.17 | -- | 0.6688 | -1.83 | -1.83 | 1.28 | 0.4068 | 0.5429 | 0.5113 | 5.71 | 1,526,428.00 | -63.39 | -100.48 | -76.67 | -151.10 | 96.01 | -- | -116.76 | -480.52 | 5.35 | -19.25 | 0.5884 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Regen BioPharma Inc | 236.58k | -851.69k | 4.11m | 1.00 | -- | -- | -- | 17.39 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -24.99m | 4.12m | 31.00 | -- | -- | -- | -- | -29.21 | -29.21 | 0.00 | -3.81 | 0.00 | -- | -- | 0.00 | -171.18 | -161.49 | -- | -213.01 | -- | -- | -- | -- | -- | -15.69 | 1.87 | -- | -- | -- | -35.90 | -- | 177.42 | -- |
| Zyversa Therapeutics Inc | 0.00 | -105.53m | 4.12m | 7.00 | -- | 0.3675 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Neximmune Inc | 0.00 | -25.86m | 4.20m | 6.00 | -- | 1.53 | -- | -- | -24.16 | -24.16 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -130.41 | -115.07 | -183.16 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| Processa Pharmaceuticals Inc | 0.00 | -9.83m | 4.23m | 13.00 | -- | 0.4758 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 4.29m | 9.00 | -- | 0.1897 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Phio Pharmaceuticals Corp's reporting currency: US Dollar USD
3.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Virtu Americas LLCas of 31 Mar 2024 | 30.91k | 0.67% |
| Cetera Investment Advisers LLCas of 31 Mar 2024 | 30.42k | 0.66% |
| Cetera Advisors LLCas of 31 Mar 2024 | 30.42k | 0.66% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 24.38k | 0.53% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 23.49k | 0.51% |
| BMO Asset Management Corp.as of 31 Mar 2024 | 20.00k | 0.44% |
| Cambridge Investment Research Advisors, Inc.as of 31 Mar 2024 | 14.23k | 0.31% |
| Tower Research Capital LLCas of 31 Mar 2024 | 5.70k | 0.12% |
| UBS Securities LLCas of 31 Mar 2024 | 1.36k | 0.03% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 19.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
